{"doi":"10.7326/m22-2216","title":"Risk Model–Based Lung Cancer Screening","abstract":"BACKGROUND: In their 2021 lung cancer screening recommendation update, the U.S. Preventive Services Task Force (USPSTF) evaluated strategies that select people based on their personal lung cancer risk (risk model-based strategies), highlighting the need for further research on the benefits and harms of risk model-based screening. OBJECTIVE: To evaluate and compare the cost-effectiveness of risk model-based lung cancer screening strategies versus the USPSTF recommendation and to explore optimal risk thresholds. DESIGN: Comparative modeling analysis. DATA SOURCES: National Lung Screening Trial; Surveillance, Epidemiology, and End Results program; U.S. Smoking History Generator. TARGET POPULATION: 1960 U.S. birth cohort. TIME HORIZON: 45 years. PERSPECTIVE: U.S. health care sector. INTERVENTION: Annual low-dose computed tomography in risk model-based strategies that start screening at age 50 or 55 years, stop screening at age 80 years, with 6-year risk thresholds between 0.5% and 2.2% using the PLCOm2012 model. OUTCOME MEASURES: Incremental cost-effectiveness ratio (ICER) and cost-effectiveness efficiency frontier connecting strategies with the highest health benefit at a given cost. RESULTS OF BASE-CASE ANALYSIS: Risk model-based screening strategies were more cost-effective than the USPSTF recommendation and exclusively comprised the cost-effectiveness efficiency frontier. Among the strategies on the efficiency frontier, those with a 6-year risk threshold of 1.2% or greater were cost-effective with an ICER less than $100 000 per quality-adjusted life-year (QALY). Specifically, the strategy with a 1.2% risk threshold had an ICER of $94 659 (model range, $72 639 to $156 774), yielding more QALYs for less cost than the USPSTF recommendation, while having a similar level of screening coverage (person ever-screened 21.7% vs. USPSTF's 22.6%). RESULTS OF SENSITIVITY ANALYSES: Risk model-based strategies were robustly more cost-effective than the 2021 USPSTF recommendation under varying modeling assumptions. LIMITATION: Risk models were restricted to age, sex, and smoking-related risk predictors. CONCLUSION: Risk model-based screening is more cost-effective than the USPSTF recommendation, thus warranting further consideration. PRIMARY FUNDING SOURCE: National Cancer Institute (NCI).","journal":"Annals of Internal Medicine","year":2023,"id":318682,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":62,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9593,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":292837,"name":"Pianpian Cao","orcid":"0000-0001-8886-9672","position":1,"is_corresponding":false},{"id":1026559,"name":"Koen de Nijs","orcid":"0000-0003-1451-0557","position":2,"is_corresponding":false},{"id":236422,"name":"Mehrad Bastani","orcid":"0000-0001-9571-9488","position":3,"is_corresponding":false},{"id":729956,"name":"Vidit Munshi","orcid":"0000-0003-0290-5148","position":4,"is_corresponding":false},{"id":1026560,"name":"Mehdi Hemmati","orcid":"0000-0002-0560-3893","position":5,"is_corresponding":false},{"id":317246,"name":"Kevin ten Haaf","orcid":"0000-0001-5006-6938","position":6,"is_corresponding":false},{"id":292838,"name":"Jihyoun Jeon","orcid":"0000-0001-7003-3412","position":7,"is_corresponding":false},{"id":317247,"name":"Martin C. Tammemägi","orcid":"0000-0002-4989-5058","position":8,"is_corresponding":false},{"id":483815,"name":"G. Scott Gazelle","orcid":null,"position":9,"is_corresponding":false},{"id":218031,"name":"Eric J. Feuer","orcid":"0000-0003-4842-7751","position":10,"is_corresponding":false},{"id":218027,"name":"Chung Yin Kong","orcid":"0000-0001-6431-7830","position":11,"is_corresponding":false},{"id":218026,"name":"Rafael Meza","orcid":"0000-0002-1076-5037","position":12,"is_corresponding":false},{"id":305675,"name":"Harry J. de Koning","orcid":"0000-0003-4682-3646","position":13,"is_corresponding":false},{"id":12632,"name":"Sylvia K. Plevritis","orcid":"0000-0003-2796-9180","position":14,"is_corresponding":false},{"id":236423,"name":"Summer S. Han","orcid":"0000-0002-2013-6883","position":15,"is_corresponding":false},{"id":236421,"name":"Iakovos Toumazis","orcid":"0000-0002-3462-2137","position":0,"is_corresponding":true}],"reference_count":67,"raw_metadata":null,"created_at":"2026-07-19T01:07:06.454099Z","pmid":"36745885","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}